Annexin Pharmaceuticals
Phase 2The therapeutic potential of ANXV is broad since its target phosphatidylserine (PS) is a factor in several diseases.
Founded
2004
Focus
Biologics
About
The therapeutic potential of ANXV is broad since its target phosphatidylserine (PS) is a factor in several diseases.
Funding History
5Total raised: $56.2M
Series B$15MFlerie InvestMay 15, 2022
Series B$22MFlerie InvestOct 15, 2021
Series A$8MKarolinska DevelopmentSep 15, 2019
Series A$8.7MHealthCapMay 15, 2018
Company Info
TypePrivate
Founded2004
LocationStockholm, Sweden
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
Basic Genomics
Pre-clinical · Stockholm
2A Pharma
Phase 1 · Stockholm
Abliva
Pre-clinical · Lund
Affibody
Phase 1 · Solna
Alligator Bioscience
Phase 1 · Lund
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile